[Reimbursement of medical expenses of the exsudative age-related macular degeneration treatment from the public health insurance].
cossekretariat@seznam.cz
S
S
Pitrová
J
J
Ernest
D000911:Antibodies, Monoclonal / Q000191:economics / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D052157:Aptamers, Nucleotide / Q000191:economics / Q000627:therapeutic use; D018153:Czech Republic; D006801:Humans; D007349:Insurance, Health, Reimbursement; D008268:Macular Degeneration / Q000188:drug therapy* / Q000191:economics*; D010778:Photochemotherapy / Q000191:economics; D011166:Porphyrins / Q000191:economics / Q000627:therapeutic use; D000069579:Ranibizumab; D000077362:Verteporfin
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D052157:Aptamers, Nucleotide; D011166:Porphyrins; D000077362:Verteporfin; C495058:pegaptanib; D000069579:Ranibizumab